You may be right about undervaluing Zantrene at $500 per dose but let's keep in mind that, as a Cardio protective drug, it will become an additional Oncology drug and not the lead drug and hence why I used $500 initially.
I want to reiterate that my $500 number was meant to be conservative but the main point I wanted to make was that even being conservative, a high share price seems realistic.
As always, I'm happy for someone to correct my conservative assumptions if they have better information to share.
You may be right about undervaluing Zantrene at $500 per dose...
-
- There are more pages in this discussion • 277 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
-0.010(0.55%) |
Mkt cap ! $307.3M | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.84 | $1.78 | $271.2K | 150.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 349 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |